BridgeBio Pharma (BBIO) posted a Q2 revenue beat, while facing higher near-term launch opex and a wider 2026-27 loss, Morgan Stanley said in a Tuesday research report.

New drug applications for the company's three late-stage programs, including the BBP-418 candidate and encaleret, have been filed with the US Food and Drug Administration, and two of the applications are in the priority review stage with hard Prescription Drug User Fee Act dates, analysts wrote.

The company faces risks related to pricing pressure on Attruby to treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis, slower frontline share gains, and potential regulatory setbacks, according to the note.

The brokerage said it now expects a 2026 loss of $2.90 from $2.61 earlier. For 2027, it expects a loss of $0.55 from $0.46 previously.

The brokerage reiterated its overweight rating on the stock and adjusted its price target to $97 per share from $98.

Price: 85.10, Change: +0.42, Percent Change: +0.50